Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma

16 novembre 2026 mis à jour par: Tethra Biosciences Inc.

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.

Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:

Group 1: Bladder cancer

Group 2: Breast cancer: Triple-negative breast cancer (TNBC)

Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])

Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)

Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC

Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)

Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])

Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers

Type d'étude

Interventionnel

Inscription (Estimé)

330

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Seoul, Corée du Sud
        • Pas encore de recrutement
        • Seoul National University Hospital
        • Contact:
      • Barcelona, Espagne
        • Pas encore de recrutement
        • Hospital Universitario Vall d'Hebron
        • Contact:
    • New York
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center (MSKCC)
        • Contact:
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • MD Anderson Cancer Center
        • Contact:
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Recrutement
        • Fred Hutchinson Cancer Center/ University of Washington
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Males or females aged ≥ 18 years.

  2. Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists

    1. For Phase 1, all tumor types may be enrolled
    2. For Phase 2, subjects will be enrolled as per the study design section above
  3. ECOG performance status of 0-2.

  4. Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease

  5. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.

  6. Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.

  7. Able to agree to and sign the informed consent and to comply with the protocol.

Exclusion Criteria:

  1. Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.

  2. Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.

  3. Subjects with a history of another primary malignancy, other than:

    1. In situ carcinomas, e.g., breast, cervix, and prostate
    2. Locally excised nonmelanoma skin cancer
    3. No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
  4. Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.

  5. Diseases that significantly affect GI absorption of THT140.

  6. Subjects who have impaired cardiac function or clinically significant cardiac disease.

  7. Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment

  8. Presence of an active infection requiring intravenous antibiotics

  9. Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism

  10. Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).

  11. Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.

  12. Major surgery/surgical therapy for any cause within 4 weeks of the first dose

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Phase 1 Dose Escalation

Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.

THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Autres noms:
  • Plogosertib
Expérimental: Phase 2

Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles.

THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Autres noms:
  • Plogosertib

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Maximum tolerated dose
Délai: 6 months

The incidence rate of dose-limiting toxicities (first cycle only) at each dose level

6 months
Overall Response Rate (ORR)
Délai: 18 months

Assessment of response criteria according to RESIST, Lugano or mSWAT.

18 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Adverse events
Délai: 24 months

Type, frequency, and severity of adverse drug reactions

24 months
AUC
Délai: 6 months

THT140 plasma concentrations

6 months
Cmax
Délai: 6 months

THT140 plasma concentrations

6 months
Tmax
Délai: 6 months

THT140 plasma concentrations

6 months
T1/2
Délai: 6 months

THT140 plasma concentrations

6 months
Disease Control Rate
Délai: 24 months

To evaluate the disease control rate (DCR) in subjects receiving THT140.

24 months
Duration of Response
Délai: 24 months

To evaluate the duration of response (DOR) in subjects receiving THT140.

24 months
Progression-free Survival
Délai: 24 months

To evaluate progression-free survival (PFS) in subjects receiving THT140.

24 months
Overall Survival
Délai: 24 months

To evaluate overall survival (OS) in subjects receiving THT140.

24 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Pharmacodynamics
Délai: 6 months

Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline.

6 months
Pharmacogenomics
Délai: 24 months

Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140.

Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed.

24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 avril 2022

Achèvement primaire (Estimé)

1 novembre 2028

Achèvement de l'étude (Estimé)

1 mai 2029

Dates d'inscription aux études

Première soumission

19 avril 2022

Première soumission répondant aux critères de contrôle qualité

27 avril 2022

Première publication (Réel)

3 mai 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner